'''Girisopam'''<ref>US Patent 4322346</ref> ('''GYKI-51189''',  '''EGIS-5810''') is a drug which is a 2,3-[[benzodiazepine]] derivative, related to [[tofisopam]]<ref>[http://www.psychotropics.dk/moleculeView/default.aspx?ID=1423&Catalogtype=A&ChapterID=1&Thissortorder=20 Psychotropics.dk]</ref> and [[zometapine]]. It has selective [[anxiolytic]] action with no [[sedative]], [[anticonvulsant]] or [[muscle relaxant]] effects.<ref>Andrási F, Horváth K, Sineger E, Berzsenyi P, Borsy J, Kenessey A, Tarr M, Láng T, Kórösi J, Hámori T. Neuropharmacology of a new psychotropic 2,3-benzodiazepine. ''Arzneimittelforschung''. 1987 Oct;37(10):1119-24.</ref><ref>Horváth K, Andrási F, Botka P, Hámori T. Anxiolytic profile of girisopam and GYKI 52,322 (EGIS 6775). Comparison with chlordiazepoxide and buspirone. ''Acta Physiologica Hungarica''. 1992;79(2):153-61.</ref><ref>Horváth EJ, Salamon C, Bakonyi A, Fekete MI, Palkovits M. [(3)H]-girisopam, a novel selective benzodiazepine for the 2, 3-benzodiazepine binding site. ''Brain Research. Brain Research Protocols''. 1999 Jul;4(2):230-5.</ref> 
